Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Encorafenib

FDA-approved product (capsule, oral), marketed as Braftovi.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Encorafenib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Colorectal adenocarcinoma
  • Colorectal cancer
  • Colorectal neoplasm
  • Cutaneous melanoma
  • Melanoma
  • Metastatic melanoma
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
B-raf serine-threonine kinase (braf) inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA49.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli44.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae35.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis64.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Encorafenib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Encorafenib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis

    NCT04074096 · start 2022-09-05

    Registered record
    Registry ID
    NCT04074096
    Conditions
    Malignant Melanoma; BRAF V600 Mutation; Brain Metastases
    Interventions
    Stereotaxic radiosurgery (SRS); Binimetinib Oral Tablet; Encorafenib Oral Capsule; Pembrolizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2022-09-05
    Completion
    2027-03-27
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalignant Melanoma; BRAF V600 Mutation; Brain Metastases
    InterventionStereotaxic radiosurgery (SRS); Binimetinib Oral Tablet; Encorafenib Oral Capsule; Pembrolizumab
    PhasePhase 2
    Registry statusActive not recruiting

  • TARGETed Therapy Drug MONITOring in DIGestive Oncology

    NCT05443087 · start 2022-08-29

    Registered record
    Registry ID
    NCT05443087
    Conditions
    Digestive Cancer; Metastatic Colorectal Cancer; Hepatocellular Carcinoma; GIST; Neuroendocrine Tumors
    Interventions
    Blood sampling to build population pharmacokinetics model
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2022-08-29
    Completion
    2027-06
    Enrolment
    330

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDigestive Cancer; Metastatic Colorectal Cancer; Hepatocellular Carcinoma; GIST +1 more
    InterventionBlood sampling to build population pharmacokinetics model
    PhaseNot applicable
    Registry statusRecruiting

  • A Study of Patient Characteristics and Treatment Patterns in Real-world Melanoma Patients Treated With Dabrafenib and Trametinib or Encorafenib and Binimetinib in Japan

    NCT07649252 · start 2022-08-01

    Registered record
    Registry ID
    NCT07649252
    Conditions
    Melanoma
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-08-01
    Completion
    2022-11-20
    Enrolment
    82

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelanoma
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer

    NCT05217446 · start 2022-07-11

    Registered record
    Registry ID
    NCT05217446
    Conditions
    Metastatic Colorectal Cancer
    Interventions
    Encorafenib; Cetuximab; Pembrolizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2022-07-11
    Completion
    2027-01-26
    Enrolment
    108

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Colorectal Cancer
    InterventionEncorafenib; Cetuximab; Pembrolizumab
    PhasePhase 2
    Registry statusActive not recruiting

  • A Relative Bioavailability Study Evaluating Two New Encorafenib Formulations

    NCT05446142 · start 2022-07-01

    Registered record
    Registry ID
    NCT05446142
    Conditions
    Healthy
    Interventions
    Encorafenib capsule formulation (CAP); Encorafenib first formulation; Encorafenib second formulation; Rabeprazole tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-07-01
    Completion
    2022-09-30
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionEncorafenib capsule formulation (CAP); Encorafenib first formulation; Encorafenib second formulation; Rabeprazole tablet
    PhasePhase 1
    Registry statusCompleted

  • Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer

    NCT05195632 · start 2022-06-02

    Registered record
    Registry ID
    NCT05195632
    Conditions
    Non-Small Cell Lung Cancer
    Interventions
    Encorafenib; Binimetinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2022-06-02
    Completion
    2026-12-14
    Enrolment
    63

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer
    InterventionEncorafenib; Binimetinib
    PhasePhase 2
    Registry statusActive not recruiting

  • Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma

    NCT04655157 · start 2021-05-28

    Registered record
    Registry ID
    NCT04655157
    Conditions
    Melanoma
    Interventions
    encorafenib; nivolumab; ipilimumab; binimetinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2021-05-28
    Completion
    2022-09-20
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelanoma
    Interventionencorafenib; nivolumab; ipilimumab; binimetinib
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

    NCT04741997 · start 2021-05-24

    Registered record
    Registry ID
    NCT04741997
    Conditions
    Melanoma Stage III; Melanoma Stage IV; BRAF V600 Mutation
    Interventions
    Encorafenib Pill; Binimetinib Pill; Nivolumab
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Recruiting
    Start
    2021-05-24
    Completion
    2027-04
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelanoma Stage III; Melanoma Stage IV; BRAF V600 Mutation
    InterventionEncorafenib Pill; Binimetinib Pill; Nivolumab
    PhaseEarly phase 1
    Registry statusRecruiting

  • PF-07284892 in Participants With Advanced Solid Tumors

    NCT04800822 · start 2021-03-17

    Registered record
    Registry ID
    NCT04800822
    Conditions
    Solid Tumor
    Interventions
    PF-07284892; lorlatinib; binimetinib; cetuximab; encorafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2021-03-17
    Completion
    2024-06-19
    Enrolment
    53

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumor
    InterventionPF-07284892; lorlatinib; binimetinib; cetuximab +1 more
    PhasePhase 1
    Registry statusTerminated

  • A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

    NCT04657991 · start 2021-01-15

    Registered record
    Registry ID
    NCT04657991
    Conditions
    Melanoma
    Interventions
    Encorafenib; Binimetinib; Pembrolizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2021-01-15
    Completion
    2026-10-30
    Enrolment
    257

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelanoma
    InterventionEncorafenib; Binimetinib; Pembrolizumab
    PhasePhase 3
    Registry statusActive not recruiting

  • A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

    NCT04607421 · start 2020-12-21

    Registered record
    Registry ID
    NCT04607421
    Conditions
    Neoplasms
    Interventions
    Encorafenib; Cetuximab; Oxaliplatin; Irinotecan; Leucovorin; 5-FU; Capecitabine; Bevacizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2020-12-21
    Completion
    2027-12-28
    Enrolment
    841

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeoplasms
    InterventionEncorafenib; Cetuximab; Oxaliplatin; Irinotecan +4 more
    PhasePhase 3
    Registry statusActive not recruiting

  • Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer

    NCT04061980 · start 2020-10-30

    Registered record
    Registry ID
    NCT04061980
    Conditions
    BRAF NP_004324.2:p.V600M; BRAF V600E Mutation Present; Metastatic Thyroid Gland Carcinoma; Refractory Thyroid Gland Carcinoma; Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8; Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v8; Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v8
    Interventions
    Binimetinib; Encorafenib; Nivolumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2020-10-30
    Completion
    2028-12-30
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBRAF NP_004324.2:p.V600M; BRAF V600E Mutation Present; Metastatic Thyroid Gland Carcinoma; Refractory Thyroid Gland Carcinoma +3 more
    InterventionBinimetinib; Encorafenib; Nivolumab
    PhasePhase 2
    Registry statusActive not recruiting

  • Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL

    NCT04324112 · start 2020-10-28

    Registered record
    Registry ID
    NCT04324112
    Conditions
    Hairy Cell Leukemia
    Interventions
    binimetinib; Encorafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2020-10-28
    Completion
    2029-06-30
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHairy Cell Leukemia
    Interventionbinimetinib; Encorafenib
    PhasePhase 2
    Registry statusActive not recruiting

  • Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE

    NCT04720768 · start 2020-06-04

    Registered record
    Registry ID
    NCT04720768
    Conditions
    Melanoma; Metastasis
    Interventions
    Binimetinib; Encorafenib; Palbociclib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2020-06-04
    Completion
    2024-12-04
    Enrolment
    78

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelanoma; Metastasis
    InterventionBinimetinib; Encorafenib; Palbociclib
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer

    NCT03803553 · start 2020-04-16

    Registered record
    Registry ID
    NCT03803553
    Conditions
    Metastatic Colon Cancer; Stage III Colon Cancer
    Interventions
    FOLFIRI Protocol; ACTIVE SURVEILLANCE; Nivolumab Protocol; Encorafenib/Binimetinib/Cetuximab Protocol; Trastuzumab + Pertuzumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2020-04-16
    Completion
    2027-12
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Colon Cancer; Stage III Colon Cancer
    InterventionFOLFIRI Protocol; ACTIVE SURVEILLANCE; Nivolumab Protocol; Encorafenib/Binimetinib/Cetuximab Protocol +1 more
    PhasePhase 3
    Registry statusActive not recruiting